Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Last reviewed: July 17, 2026 Last updated: July 17, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Similarly, several previous studies demonstrated DNA damage following excess iron deposition in various tissues 50,61,62
This cohort was merged with the SABR trial, a phase II trial enrolling patients with stage IV colorectal, lung, and kidney tumors treated with SABR plus anti-PD-L1 antibodies 42,43
Science 339 , 286291 (2013)
US$ 23.55
US$ 29.52
US$ 25.53
US$ 26.20
